3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Sarcoma, Kaposi
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Lymphoma
1
Epstein-Barr Virus Infections
1
Acquired Immunodeficiency Syndrome
1
Interventions
plerixafor
1
fludarabine phosphate
1
fludarabine
1
abemaciclib
1
Thiotepa
1
Tacrolimus
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Melphalan
1
Maraviroc
1
Genes
1
Cyclophosphamide
1
Busulfan
1
Alemtuzumab
1
AZD 6244
1
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Acquired Immunodeficiency Syndrome
×
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
×
Clear all
NCT02229981
2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2
Withdrawn